130 related articles for article (PubMed ID: 32559398)
1. Effects of
Lin X; Chen H; Ni L; Yu Y; Luo Z; Liao L
Pharmacogenomics; 2020 Aug; 21(12):863-870. PubMed ID: 32559398
[No Abstract] [Full Text] [Related]
2. Clinical and genetic factors associated with warfarin maintenance dose in northern Chinese patients with mechanical heart valve replacement.
Liu R; Cao J; Zhang Q; Shi XM; Pan XD; Dong R
Medicine (Baltimore); 2017 Jan; 96(2):e5658. PubMed ID: 28079798
[TBL] [Abstract][Full Text] [Related]
3. [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
Lou Y; Han L; Li Y; Zhang X; Liu Z; Tang M; Yu H; Wang W; Xu J; Liu H; Li Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):367-71. PubMed ID: 24928022
[TBL] [Abstract][Full Text] [Related]
4. Impact of
Li W; Zhao P; Chen L; Lai X; Shi G; Li L; Dong J
Pharmacogenomics; 2020 Jan; 21(2):101-110. PubMed ID: 31854268
[No Abstract] [Full Text] [Related]
5. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.
Li J; Yang W; Xie Z; Yu K; Chen Y; Cui K
BMC Cardiovasc Disord; 2018 May; 18(1):96. PubMed ID: 29776386
[TBL] [Abstract][Full Text] [Related]
6. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
7. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
8. Genetic factors (VKORC1, CYP2C9, EPHX1, and CYP4F2) are predictor variables for warfarin response in very elderly, frail inpatients.
Pautas E; Moreau C; Gouin-Thibault I; Golmard JL; Mahé I; Legendre C; Taillandier-Hériche E; Durand-Gasselin B; Houllier AM; Verrier P; Beaune P; Loriot MA; Siguret V
Clin Pharmacol Ther; 2010 Jan; 87(1):57-64. PubMed ID: 19794411
[TBL] [Abstract][Full Text] [Related]
9. Polymorphisms of vitamin K-related genes (EPHX1 and VKORC1L1) and stable warfarin doses.
Chung JE; Lee KE; Chang BC; Gwak HS
Gene; 2018 Jan; 641():68-73. PubMed ID: 29054760
[TBL] [Abstract][Full Text] [Related]
10. Genetic Associations With Stable Warfarin Dose Requirements in Han Chinese Patients.
Xu Q; Zhang S; Wu C; Xiong Y; Niu J; Li F; Zhu J; Shen L; Zhu B; Xing Q; He L; Chen L; Li M; Li H; Ge J; Qin S
J Cardiovasc Pharmacol; 2021 Jul; 78(1):e105-e111. PubMed ID: 33958549
[TBL] [Abstract][Full Text] [Related]
11. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
12. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
[TBL] [Abstract][Full Text] [Related]
13. Genetic determinants of warfarin dosing in the Han-Chinese population.
Lee MT; Chen CH; Chou CH; Lu LS; Chuang HP; Chen YT; Saleem AN; Wen MS; Chen JJ; Wu JY; Chen YT
Pharmacogenomics; 2009 Dec; 10(12):1905-13. PubMed ID: 19958090
[TBL] [Abstract][Full Text] [Related]
14. Effect of VKORC1, CYP2C9, CFP4F2, and GGCX Gene Polymorphisms on Warfarin Dose in Japanese Pediatric Patients.
Wakamiya T; Hokosaki T; Tsujimoto S; Kadota K; Nakano Y; Watanabe S; Iwamoto M; Yanagimachi M; Ito S
Mol Diagn Ther; 2016 Aug; 20(4):393-400. PubMed ID: 27262824
[TBL] [Abstract][Full Text] [Related]
15. Genetic Factors Influencing Warfarin Dose in Han Chinese Population: A Systematic Review and Meta-Analysis of Cohort Studies.
Zhao Z; Zhao F; Wang X; Liu D; Liu J; Zhang Y; Hu X; Zhao M; Tian C; Dong S; Jin P
Clin Pharmacokinet; 2023 Jun; 62(6):819-833. PubMed ID: 37273173
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
17. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
Gu Q; Kong Y; Schneede J; Xiao YB; Chen L; Zhong QJ; Wang XF; Hao J; Chen BC; Chen JJ
Eur J Clin Pharmacol; 2010 Dec; 66(12):1217-27. PubMed ID: 20842355
[TBL] [Abstract][Full Text] [Related]
18. Exon sequencing and association analysis of EPHX1 genetic variants with maintenance warfarin dose in a multiethnic Asian population.
Chan SL; Thalamuthu A; Goh BC; Chia KS; Chuah B; Wong A; Lee SC
Pharmacogenet Genomics; 2011 Jan; 21(1):35-41. PubMed ID: 21192345
[TBL] [Abstract][Full Text] [Related]
19. Prediction of warfarin maintenance dose in Han Chinese patients using a mechanistic model based on genetic and non-genetic factors.
Lu Y; Yang J; Zhang H; Yang J
Clin Pharmacokinet; 2013 Jul; 52(7):567-81. PubMed ID: 23515956
[TBL] [Abstract][Full Text] [Related]
20. CYP2C9, VKORC1, and CYP4F2 polymorphisms and pediatric warfarin maintenance dose: a systematic review and meta-analysis.
Takeuchi M; Kobayashi T; Biss T; Kamali F; Vear SI; Ho RH; Bajolle F; Loriot MA; Shaw K; Carleton BC; Hamberg AK; Wadelius M; Hirono K; Taguchi M; Wakamiya T; Yanagimachi M; Hirai K; Itoh K; Brandão LR; Ito S
Pharmacogenomics J; 2020 Apr; 20(2):306-319. PubMed ID: 31673144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
